Introduction {#Sec1}
============

Increased pro-inflammatory markers and oxidative stress occurs in adipose tissues are the two factors that may play a key role in the incidence of metabolic-related comorbidities among patients with metabolic disorders \[[@CR1]\]. Increased chronic inflammation is associated with increased risk of metabolic disorders, including type 2 diabetes mellitus (T2DM) \[[@CR2]\] and arteriosclerosis, endothelial dysfunction, vascular calcification, increased activity of metalloproteinases, oxidative damage, and degradation of collagen \[[@CR3]--[@CR5]\]. It was reported that *metabolic syndrome (MetS*) is associated with a 2-fold increased risk of cardiovascular disease (CVD) over the next 5 to 10 years \[[@CR6]\]. Inflammatory cytokines including interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α) are usually produced by different cells including endothelial, immune and arterial smooth muscle cells inducing the migration of additional immune cells into the atherosclerotic lesion and the activation of the acute phase C-reactive protein (CRP) in the liver \[[@CR7], [@CR8]\]. Increased levels of CRP are associated with increased risk of CVD and diabetes \[[@CR9], [@CR10]\]. In addition to CRP, other inflammatory biomarkers such as IL-6 and TNF-α may be correlated with the development of CVD in diabetic patients \[[@CR11]\].

Complementary therapies such as antioxidants supplementation are recommended in patients with metabolic abnormalities to improve their nutritional status and boost their immune system \[[@CR12]\]. Existing evidence has proved the beneficial effects of several antioxidants supplements including pentoxifylline \[[@CR13]\] and lycopene \[[@CR14]\] on reducing inflammation. Available data regarding the effects of alpha-lipoic acid (ALA) supplementation on inflammatory markers are controversial. In a study by Carbonelli et al. \[[@CR15]\], obese Caucasian people showed significant reduction in CRP and TNF-α concentrations following ALA supplementation (800 mg/day) for 4 months. ALA supplementation (600--1000 mg/day) during a period ranging from 2 wk. to 1 year in patients with impaired glucose tolerance showed contradictory results. Zhang et al. \[[@CR16]\] demonstrated that ALA supplementation decreased TNF-α and IL-6 while increased adiponectin levels, however others did not observe any beneficial effects of ALA on inflammatory markers \[[@CR17], [@CR18]\]. Discrepancies in these findings may be due to differences in study design, characteristics of study populations, dosage of ALA used and duration of the intervention.

We are aware of no systematic review or meta-analyses of randomized controlled trials (RCTs) evaluating the effect of ALA supplementation on inflammatory markers among patients with MetS and related disorders. Thus, the current meta-analysis was performed to summarize the available evidence regarding the effect of ALA supplementation on inflammatory markers among patients with MetS and related disorders.

Materials and methods {#Sec2}
=====================

Search strategy and selection studies {#Sec3}
-------------------------------------

We searched the following databases until November 2017: PubMed, MEDLINE, EMBASE, Web of Science, and Cochrane Central Register of Controlled Trials. Additionally, a manual search was conducted among the references lists of all eligible articles and review studies to identify potential articles that were not captured by the electronic searches. Three authors (VO, MM and MA) independently performed the literature search to retrieve RCTs that have examined the association between ALA supplementation and the inflammatory markers by using the following MeSH and text keywords: patients \["Mets" OR "disorders related to MetS" OR "diabetes" OR "T1DM" OR "T2DM" OR "overweight" OR "obese" OR "chronic kidney disease (CKD)" OR "hypertension" OR "high blood pressure" OR "dyslipidemia" OR "CVD"\], intervention ("alpha-lipoic acid" OR "ALA" OR "α-lipoic acid" AND "supplementation" OR "intake"), and outcomes \["CRP" OR "IL-6" OR "TNF-α"\]. Eligible studies were restricted to those RCTs published in English language.

Inclusion and exclusion criteria {#Sec4}
--------------------------------

RCTs were selected using the following inclusion criteria: being a placebo-controlled randomized trial (either parallel or cross-over designs), human studies conducted in adults, the target population was patients diagnosed with metabolic diseases, and studies reported mean changes between pre- and post-intervention CRP and/or IL-6 and/or TNF-α following ALA supplementation for the intervention and placebos groups. Other types of human studies (cross-sectional, cohort studies), animal, in vitro studies, and review papers were excluded. Case reports or cases series, and the studies did not achieve the minimum quality assessment score, those receiving any non-steroidal anti-inflammatory drug or ALA supplements within the last month were also excluded from the study.

Data extraction and quality assessment {#Sec5}
--------------------------------------

Three authors (VO, MM, and MA) reviewed each trial and extracted all related data, independently. The disagreement among them was resolved by discussion with a fourth author (ZA). The quality of the included RCTs was assessed using the Cochrane Collaboration risk of bias tool based on the following information: randomization generation, allocation concealment, blinding of participants and outcome assessment, incomplete outcome data, and selective outcome reporting, as well as the other sources of bias. The extracted data included: first author, publication year, demographical variables, study design, sample size, dose of intervention, duration of study, type of intervention, type of disease, the mean and standard deviation (SD) for CRP, IL-6, and TNF-α.

Data synthesis and statistical analysis {#Sec6}
---------------------------------------

We preformed a comprehensive electronic and manual search to avoid publication bias. Additionally, Egger's regression test was used to assess publication bias statistically \[[@CR19]\]. Statistical heterogeneity was assessed using Cochran's Q and I-square (I^2^) tests \[[@CR20]\]. I^2^ greater than 50% or *P* \< 0.05 was considered as significant heterogeneity. We estimated the difference between intervention (ALA supplementation) and placebo group by calculating the standardized mean difference (SMD) with 95% confidence interval (CI) using STATA software version 12.0 (Stata Corp., College Station, TX) and RevMan V.5.3 software (Cochrane Collaboration, Oxford, UK). Since the indications could effect on pooled SMD were different between included studies, we used random-effects models to perform meta-analyses. Subgroup and sensitivity analyses were conducted to assess the source of heterogeneity and to explore the contribution of each study to the reliability of the pooled mean difference, respectively. *P*-values \< 0.05 were considered as statistically significant.

Results {#Sec7}
=======

The process of the step by step study selection has shown in Additional file [1](#MOESM1){ref-type="media"}. Overall, 18 trials out of 912 potential citations were found to be eligible for this meta-analysis. Seven studies were RCTs design, and eleven were randomized, double-blind, placebo-controlled trials. Eleven trials have assessed the effects of ALA supplementation on CRP \[[@CR21]--[@CR31]\], eleven on IL-6 \[[@CR16], [@CR22]--[@CR25], [@CR30]--[@CR35]\], and nine on TNF-α levels \[[@CR16], [@CR22], [@CR24], [@CR25], [@CR28], [@CR32], [@CR33], [@CR36], [@CR37]\]. Intervention duration among included studies varied from 2 weeks to 12 months. The dosage of ALA supplements ranged from 300 to 600 (mg/day). Location of studies included; four studies in Italy \[[@CR25], [@CR28], [@CR29], [@CR33]\], three in Iran \[[@CR23], [@CR27], [@CR37]\], three in China \[[@CR16], [@CR21], [@CR22]\], two in Egypt \[[@CR35], [@CR36]\], one in Spain \[[@CR30]\], one in Romania \[[@CR32]\], two in United States \[[@CR31], [@CR34]\], one in Korea \[[@CR26]\], and one in New Zealand \[[@CR24]\]. Details of the included studies are summarized in Table [1](#Tab1){ref-type="table"}. The quality of included trials is presented in Additional file [2](#MOESM2){ref-type="media"}.Table 1Characteristics of included studiesAuthors (Ref)Publication yearSample size (control/intervention)Country/populationIntervention (name and daily dose)DurationPresented dataAge (y) (control, intervention)ResultsHong et al. \[[@CR22]\]201732/30China/patients with diabetic nephropathy450 mg ALA (IV) + 20 μg alprostadil2 weeksCRP, IL-6, TNF-α65.82 ± 11.63, 67.24 ± 10.81Decreased CRP, IL-6 and TNF-αSardu et al. \[[@CR25]\]201740/33Italy/overweight patients with atrial fibrilation600 mg ALA12 monthsCRP, IL-6, TNF-α61.5 ± 8.1, 58.8 ± 6.7Decreased CRP, IL-6 and TNF-αHuerta et al. \[[@CR30]\]201621/19Spain/overweight and obese women300 mg ALA10 weeksCRP, IL-6range: 20--50Decreased CRP and IL-6Huerta et al. \[[@CR30]\]201621/17Spain/overweight and obese women300 mg ALA + 1.3 g EPA10 weeksCRP, IL-6range: 20--50Decreased CRPMarfella et al. \[[@CR28]\]201521/22Italy/overweight patients with cardiomyopathy600 mg ALA12 monthsCRP, TNF-α63.9 ± 5.2, 63.7 ± 6.5Decreased CRP and TNF-αSafa et al. \[[@CR37]\]201431/30Iran/patients with ESRD on hemodialysis600 mg ALA8 weeksTNF-α55.20 ± 13.43, 59.3 ± 10.47No effectAhmadi et al. \[[@CR23]\]201324/20Iran/hemodialysis patients600 mg ALA2 monthsCRP, IL-648.9 ± 12.5, 48.8 ± 11.2Decreased CRP and IL-6Ahmadi et al. \[[@CR23]\]201324/24Iran/hemodialysis patients600 mg ALA + 400 IU vitamin E2 monthsCRP, IL-648.9 ± 12.5, 53.2 ± 9.8Decreased CRP and IL-6El-Nakib et al. \[[@CR35]\]201322/22Egypt/patients with CRF on hemodialysis600 mg ALA3 monthsIL-646.2 ± 14.4, 49.1 ± 16.2No effectHegazy et al. \[[@CR36]\]201315/15Egypt/patients with T1DM600 mg ALA + insulin4 monthsTNF-α11.1 ± 2.3, 11.9 ± 1.4Decreased TNF-αCinteza al. \[[@CR32]\]201314/14Romania/post acute stroke patients600 mg ALA + other nutrients2 weeksIL-6, TNF-α67.1 ± 10.85, 64 ± 10.85Decreased IL-6 and TNF-αNasole et al. \[[@CR33]\]20136/10Italy/patients with chronic leg wound and metabolic disease600 mg ALA2 weeksIL-6, TNF-α72,59Decreased IL-6 and TNF-αNasole et al. \[[@CR33]\]20136/10Italy/patients with chronic leg wound and metabolic disease600 mg R-(+)-lipoic acid (RLA)2 weeksIL-6, TNF-α72,72Decreased IL-6 and TNF-αKhabbazi et al. \[[@CR27]\]201228/24Iran/patients with ESRD on hemodialysis600 mg ALA8 weeksCRP54.04 ± 13.96, 53.83 ± 13.29Decreased CRPManning et al. \[[@CR24]\]201239/34New Zealand/patients with MetS600 mg ALA12 monthsCRP, IL-6, TNF-α57 ± 9, 55 ± 10No effectZhang et al. \[[@CR16]\]20119/13China/obese patients with impaired glucose tolerance600 mg ALA (IV)2 weeksIL-6, TNF-α52.6 ± 6.2, 52.5 ± 8.2Decreased IL-6 and TNF-αXiang et al. \[[@CR21]\]201130/30China/patients with impaired fasting glucose600 mg ALA (IV)3 weeksCRP58 ± 9, 58 ± 10Decreased CRPGianturco et al. \[[@CR29]\]20097/7Italy/patients with NIDDM400 mg ALA4 weeksCRP58 ± 16, 61 ± 7No effectChang et al. \[[@CR26]\]200725/25Korea/diabetic ESRD patients on hemodialysis600 mg ALA12 weeksCRP66 ± 7, 63 ± 6No effectSola et al. \[[@CR34]\]200514/15USA/patients with MetS300 mg ALA4 weeksIL-644 ± 13, 46 ± 15Decreased IL-6Sola et al. \[[@CR34]\]200514/15USA/patients with MetS300 mg ALA + 150 mg irbesartan4 weeksIL-644 ± 13, 48 ± 12Decreased IL-6Romos et al. \[[@CR31]\]201228/30USA/patients with CKD600 mg ALA + 666 IU tocopherols8 weeksCRP, IL-664.5 ± 8.8, 58.6 ± 12.0Decreased IL-6*ALA* alpha-lipoic acid, *CRF* chronic renal failure, *CKD* chronic kidney disease, *ESRD* end-stage renal disease, *IV* intravascular, *IL-6* interlokin-6, *CRP* C-reactive protein, *MetS* metabolic syndrome, *NIDDM* non-insulin-dependent diabetes mellitus, *TNF-α* tumor necrosis factor alpha, *T1DM* type 1 diabetes mellitus, *T2DM* type 2 diabetes mellitus

Main outcomes {#Sec8}
-------------

The results of current meta-analysis showed that ALA supplementation significantly decreased CRP (SMD = − 1.52; 95% CI, − 2.25, − 0.80; *P* \< 0.001; I^2^: 93.7), IL-6 (SMD = − 1.96; 95% CI, − 2.60, − 1.32; *P* \< 0.001; I^2^: 90.6), and TNF-α levels (SMD = − 2.62; 95% CI, − 3.70, − 1.55; *P* \< 0.001; I^2^: 94.3) in patients with MetS and related disorders (Table [2](#Tab2){ref-type="table"} and Fig. [1](#Fig1){ref-type="fig"}).Table 2Estimation of the standardized difference means of related indictors with CI 95% between the intervention and placebo groupsVariablesNumber of studyStandardized mean differenceCI 95%HeterogeneityI^2^ (%)Q*P*-valueCRPIntervention group (after vs. before)11−0.88−1.55, − 0.2192.4130.85\< 0.001Placebo group (after vs. before)11−0.29− 0.67, 0.0980.350.87\< 0.001Change intervention group vs. placebo group13−1.52−2.25, −0.8093.7191.17\< 0.001IL-6Intervention group (after vs. before)13−0.99−1.48, − 0.5185.079.92\< 0.001Placebo group (after vs. before)130.03−0.16, 0.2217.814.590.264Change intervention group vs. placebo group15−1.96−2.60, − 1.3290.6149.58\< 0.001TNF-αIntervention group (after vs. before)10−1.41−2.03, −0.7987.069.13\< 0.001Placebo group (after vs. before)10−0.33− 0.72, 0.0571.431.50\< 0.001Change intervention group vs. placebo group10−2.62−3.70, −1.5594.3157.51\< 0.001*IL-6* interlokin-6, *CRP* C-reactive protein, *TNF-α* tumor necrosis factor alphaFig. 1**a**-**c** Meta-analysis glycemic control standardized mean differences estimates for (**a**) high-sensitivity C-reactive protein, (**b**) for interlokin-6, and (**c**) for tumor necrosis factor alpha in alpha-lipoic acid supplements and placebo groups (CI = 95%)

We also performed subgroup analyses according to geographic area (Asia, European, USA, Oceania, and Africa), dosage of ALA supplements (\> 600 vs. ≤600 mg/day), co-administration with other nutrients (ALA vs. ALA plus other nutrients), duration of the intervention (≥8 vs. \< 8 weeks), and type of diseases (diabetic, ESRD vs. other diseases). We found that heterogeneity may decrease by duration of the intervention (\< 8 weeks = I^2^: 89.9 and ≥ 8 weeks = I^2^:85.1 vs. overall I^2^:90.6%) and type of diseases (diabetic = I^2^: 75.1 and other = I^2^:89.5 vs. overall I^2^:90.6%) for IL-6 and type of diseases (diabetic = I^2^: 92.8 and other = I^2^:94.0 vs. overall I^2^:94.3%) for TNF-α levels (\< 8 weeks = I^2^: 88.2 and ≥ 8 weeks = I^2^:92.1 vs. overall I^2^:94.5%). The detailed of subgroup analysis are presented in Table [3](#Tab3){ref-type="table"}.Table 3The assess of association between alpha-lipoic acid supplementation on inflammatory markers based on subgroup analysisVariablesNumber of SMD includedSubgroupsPooled OR (random effect)95% CII^2^ (%)overall I^2^(%)CRPGeographic area6Asia−1.20−2.02, − 0.3890.893.75European−2.52−4.26, −0.7894.81USA−0.46− 0.98, 0.07--1Oceania0.05−0.41, 0.51--Dosage of ALA (mg/day)4\< 600−1.29−2.16, −0.4281.49≥600−1.64−2.61, −0.6695.4Type of intervention9ALA−1.63−2.67, −0.5895.34ALA plus other nutrients−1.30−2.10, −0.5085.0Duration of study (week)10≥8−1.50−2.35, −0.6594.43\< 8−1.63−2.93, −0.3288.6Type of diseases3Diabetic−1.63−2.93, −0.3288.610Other−1.50−2.35, −0.6594.4IL-6Geographic area4Asia−2.18−3.34, −1.0288.790.66European−1.75−2.71, −0.7887.43USA−4.10−7.68, −0.5296.31Oceania−0.26−0.72, 0.20--1Africa−0.57−1.17, 0.03--Dosage of ALA (mg/day)5\< 600−3.59−5.50, −1.6894.810≥600−1.22− 1.70, −0.7478.4Type of intervention8ALA−2.00−2.88, −1.1190.97ALA plus other nutrients−1.98−3.01, −0.9591.7Duration of study (week)8≥8−1.07− 1.62, −0.5285.17\< 8−3.30−4.61, −1.9989.9Type of diseases2Diabetic−3.40−5.13, −1.6675.113Other−1.72−2.35, − 1.0989.5TNF-αGeographic area3Asia−2.44−4.67, −0.2195.994.35European−2.63−3.87, −1.3987.21Oceania−0.34− 0.80, 0.12--1Africa−6.35−8.16, −4.54--Dosage of ALA (mg/day)1\< 600−2.14−2.77, −1.51--9≥600−2.71−3.94, − 1.4894.7Type of intervention6ALA−2.56−4.08, −1.0395.84ALA plus other nutrients−2.73−4.26, −1.2089.3Duration of study (week)5≥8−2.78−4.57, −0.9996.85\< 8−2.40−3.46, −1.3380.2Type of diseases3Diabetic−4.68−7.82, −1.5592.87Other−1.89−3.04, −0.7394.0*ESRD* end-stage renal disease, *IL-6* interlokin-6, *CRP* C-reactive protein, *TNF-α* tumor necrosis factor alpha

In sensitivity analysis, we found no significant difference between the pre- and post-sensitivity analysis for all inflammatory markers. The smallest and greatest pooled SMDs in the sensitivity analyses for the level of inflammatory markers are shown in Additional file [3](#MOESM3){ref-type="media"}. Egger's regression tests showed no significant publication bias for the effects of ALA on CRP (B = − 11.35, *P* = 0.01). We found publication bias for IL-6 (B = − 6.88, *P* = 0.00) and TNF-α (B = − 7.28, P = 0.01), so we non parametric method was applied (Duval and Tweedie) to estimate the findings of censored studies. Findings showed that the summary of effect size for IL-6 and TNF-α did not significantly changed between before and after inclusion of censored studies for CRP (SMD = − 1.69; 95% CI, − 2.48, − 0.90), IL-6 (SMD = − 1.96; 95% CI, − 2.60, − 1.32), and TNF-α (SMD = − 2.62; 95% CI, − 3.70, − 1.55).

Discussion {#Sec9}
==========

This systematic review and meta-analysis assessed the effect of ALA supplementation on inflammatory markers in patients with MetS and related disorders. Our findings supported the beneficial impact of ALA administration on lowering inflammatory markers in patients suffering from metabolic syndrome and related disorders.

Few studies have reported the beneficial effects of antioxidant supplementation on inflammatory cytokines. In a meta-analysis conducted by Ju et al. \[[@CR38]\], selenium supplementation significantly decreased serum CRP levels in patients with coronary heart disease, suggesting its potential impact on reducing inflammation in chronic conditions. In addition, supplementation with vitamin E in the form of either α-tocopherol or γ-tocopherol resulted in a significant reduction in CRP concentrations \[[@CR39]\]. Available information regarding the effects of ALA supplementation on inflammatory cytokines is inconclusive. ALA supplementation for 12 months significantly decreased serum levels of common markers of inflammation in ablated patients \[[@CR25]\]. Furthermore, dietary supplementation with ALA for 10 weeks significantly improved systemic inflammation and cardiovascular disease-related risk factors in healthy overweight women \[[@CR30]\]. However, no benefits of resveratrol supplementation were reported on cardiovascular risk factors in the meta-analysis conducted by Sahebkar et al. \[[@CR40]\]. In another study, taking ALA supplements for 8 weeks did not affect IL-8 and TNF-α levels in hemodialysis patients \[[@CR37]\]. Increased inflammatory markers, especially TNF-α, might promote insulin resistance, and alter expression of cytokines in adipose tissues which is considered an important link between *MetS* and insulin resistance \[[@CR41]\]. In addition, high levels of inflammatory markers in diabetic patients and those suffering from diabetic nephropathy are positively correlated with the severity of albuminuria \[[@CR42]\]. Local inflammation plays also an important role in the development of diabetic retinopathy \[[@CR43]\].

ALA intake may reduce inflammatory markers through scavenging free radicals, down-regulating pro-inflammatory redox-sensitive signal transduction processes including nuclear factor kappa B translocation, leading to lower release of other free radicals and cytotoxic cytokines \[[@CR44], [@CR45]\]. Moreover, ALA administration improves cellular antioxidant capacity and phases 2 enzymes such as catalase, reduced glutathione, glutathione reductase, and glutathione-S-transferase \[[@CR46]\]. ALA can also inhibit the activation of serine kinases including IKKβ to suppress inflammatory cytokines \[[@CR47]\]. Zhang et al. \[[@CR48]\] mentioned to ALA potential to inhibit TNF-α-induced I kappa B kinase activation. It is speculated that the ALA treatment effects might be influenced by its baseline values and improved blood levels over time. In the current meta-analysis it was not possible to consider the effect of baseline ALA values in determining the impact of it on inflammatory markers. Furthermore, different geographical latitudes where study conducted might further complicate the effect of baseline ALA values. Overall, on top of those explained above, different study designs, sample size, different dosages of ALA used along with characteristics of study participants might explain the discrepancies among different studies.

There are several strengths for this study. Higher numbers of studies included in this analysis and longer period of supplementation in included trials have added to the value of this meta-analysis. All included studies were placebo-controlled randomized trials with acceptable methodological quality and the least probable chance of bias. Further, we relied on independent judgment in which different reviewers independently performed the systematic review process.

The current meta-analysis had a few limitations. There were few eligible RCTs, and most of them had a modest number of participants. Various doses of ALA were administered for intervention in the included studies. We were unable to evaluate the dose response association between supplementation dose and inflammatory markers due to the low number of studies included. In addition, we did not evaluate the residual confounding and bias of each study that could not be addressed through pooling. Considerable heterogeneity across studies made our findings complicated to interpret the main outcomes. Thus, evaluation of heterogeneity is a crucial part of any meta-analysis.

Conclusions {#Sec10}
===========

Overall, the current meta-analysis supported the beneficial impacts of ALA administration on decreasing inflammatory markers such as CRP, IL-6 and TNF-α among patients with MetS and related disorders.
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